Inozyme Pharma Inc (INZY) concluded trading on Thursday at a closing price of $1.42, with 3.63 million shares of worth about $5.15 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -64.50% during that period and on May 15, 2025 the price saw a gain of about 5.19%. Currently the company’s common shares owned by public are about 64.47M shares, out of which, 43.75M shares are available for trading.
Stock saw a price change of 14.52% in past 5 days and over the past one month there was a price change of 42.40%. Year-to-date (YTD), INZY shares are showing a performance of -48.74% which decreased to -68.51% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.72 but also hit the highest price of $6.24 during that period. The average intraday trading volume for Inozyme Pharma Inc shares is 771.16K. The stock is currently trading 21.53% above its 20-day simple moving average (SMA20), while that difference is up 35.27% for SMA50 and it goes to -51.80% lower than SMA200.
Inozyme Pharma Inc (NASDAQ: INZY) currently have 64.47M outstanding shares and institutions hold larger chunk of about 57.00% of that.
The stock has a current market capitalization of $91.68M and its 3Y-monthly beta is at 1.39. It has posted earnings per share of -$1.68 in the same period. It has Quick Ratio of 2.19 while making debt-to-equity ratio of 1.48. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for INZY, volatility over the week remained 18.55% while standing at 16.61% over the month.
Stock’s fiscal year EPS is expected to rise by 13.97% while it is estimated to increase by 18.92% in next year. EPS is likely to grow at an annualized rate of 19.48% for next 5-years, compared to annual growth of -13.98% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Raymond James on December 12, 2024 offering an Outperform rating for the stock and assigned a target price of $26 to it. Coverage by Stifel stated Inozyme Pharma Inc (INZY) stock as a Buy in their note to investors on September 12, 2024, suggesting a price target of $16 for the stock. On August 13, 2024, Jefferies Resumed their recommendations, while on May 30, 2024, Wells Fargo Initiated their ratings for the stock with a price target of $14. Stock get a Buy rating from Jefferies on March 23, 2023.
